6-K
Sofgen Pharma S.A. (PROCF)
UNITED STATES
SECURITIESAND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATEISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-40851
ProcapsGroup, S.A.
(Translation of registrant’s name in English)
9 rue de Bitbourg, L-1273
Luxembourg
Grand Duchy of Luxembourg
R.C.S. Luxembourg: B253360
Tel : +356 7995-6138
(Address of Principal ExecutiveOffices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ **** Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
INFORMATION CONTAINEDIN THIS REPORT ON FORM 6-K
Earnings ConferenceCall
On August 30, 2022, Procaps Group, S.A. issued a press release announcing that it will host a conference call and webcast at 12 p.m. Eastern time, on August 31, 2022, to discuss its second quarter and first half 2022 results (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated by reference herein.
Exhibit Index
| Exhibit Number | Exhibit Title |
|---|---|
| 99.1 | Press Release of Procaps Group, S.A. dated August 30, 2022 – Procaps Group to Host Second Quarter and First Half 2022 Conference Call on Wednesday. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROCAPS GROUP, S.A. | |
|---|---|
| By: | /s/ Ruben Minski |
| Name: | Ruben Minski |
| Title: | Chief Executive Officer |
Dated: August 30, 2022
2
Exhibit99.1
ProcapsGroup to Host Second Quarter and First Half 2022
Conference Call on Wednesday
MIAMI,USA - BARRANQUILLA, COL – August 30, 2022 – Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that will host a conference call and webcast at 12 p.m. Eastern time, on August 31, 2022, to discuss the second quarter and first half 2022 results.
The Earnings Release and Financials Statements can be found on Procaps website - https://investor.procapsgroup.com/.
To access the call, please use the following information:
| Date: | Wednesday, August 31, 2022 |
|---|---|
| Time: | 12:00 p.m. ET |
| Toll Free dial-in number: | 1-844-204-8586 |
| Toll/International dial-in number: | 1-412-317-6346 |
| Conference ID: | Procaps Group |
The conference call will be broadcast live and available for replay at https://bit.ly/PROC2Q22 and via the investor relations section of Procaps’ website here.
A telephone replay will be available approximately two hours after the call and will run through September 12, 2022, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 8496276.
AboutProcaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
InvestorContact:
Melissa Angelini
ir@procapsgroup.com
+1 754 260-6476
investor.procapsgroup.com